{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:04:18Z","timestamp":1791385458774,"version":"4.3.3"},"reference-count":103,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.modpat.2025.100925","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T16:25:39Z","timestamp":1761668739000},"page":"100925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-Low and Ultralow Categories"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5009-5525","authenticated-orcid":false,"given":"Emad A.","family":"Rakha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puay Hoon","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke R.","family":"Van Bockstal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly H.","family":"Allison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edi","family":"Brogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Callagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Cserni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam","family":"Jaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Foschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helenice","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina","family":"Kulka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Provenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer M.","family":"Shaaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary M.","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Vincent-Salomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rin","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soha","family":"ElSheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"De Brot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Canas-Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Marchi\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri V.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien H.M.","family":"van Deurzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Deb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian O.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Schnitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Pinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecily","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.modpat.2025.100925_bib1","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.modpat.2025.100925_bib2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fphar.2015.00283","article-title":"Role of ErbB receptors in cancer cell migration and invasion","volume":"6","author":"Appert-Collin","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.modpat.2025.100925_bib3","first-page":"1","article-title":"The paradoxical functions of EGFR during breast cancer progression","volume":"2","author":"Ali","year":"2017","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.modpat.2025.100925_bib4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jnci\/95.2.142","article-title":"Quantitative association between HER-2\/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer","volume":"95","author":"Konecny","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.modpat.2025.100925_bib5","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.2007.14.8197","article-title":"Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations","volume":"27","author":"Sauter","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib6","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1073\/pnas.89.12.5321","article-title":"ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization","volume":"89","author":"Kallioniemi","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.modpat.2025.100925_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2020.02.016","article-title":"Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond","volume":"72","author":"Marchi\u00f2","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.modpat.2025.100925_bib8","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","article-title":"Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials","volume":"22","author":"Bradley","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1176309","article-title":"Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test","volume":"10","author":"Sajjadi","year":"2023","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.modpat.2025.100925_bib10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.modpat.2025.100925_bib11","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.modpat.2025.100925_bib12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.modpat.2025.100925_bib13","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/jcp.53.12.890","article-title":"Recommendations for HER2 testing in the UK","volume":"53","author":"Ellis","year":"2000","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.modpat.2025.100925_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/jclinpath-2014-202571","article-title":"Updated UK Recommendations for HER2 assessment in breast cancer","volume":"68","author":"Rakha","year":"2015","journal-title":"J Clin Pathol"},{"issue":"Suppl 3","key":"10.1016\/j.modpat.2025.100925_bib15","first-page":"S1","article-title":"HER2 testing in breast cancer: NCCN Task Force report and recommendations","volume":"4","author":"Carlson","year":"2006","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.modpat.2025.100925_bib16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1136\/jcp.2010.084863","article-title":"Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations","volume":"64","author":"Lambein","year":"2011","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.modpat.2025.100925_bib17","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1200\/JCO.2008.19.7939","article-title":"Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial","volume":"27","author":"Dowsett","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JCO.2010.28.6450","volume":"29","author":"Valero","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib19","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.19.01455","article-title":"NSABP B-47\/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2+","volume":"38","author":"Fehrenbacher","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11864-013-0262-4","article-title":"Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future","volume":"15","author":"Subbiah","year":"2014","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.modpat.2025.100925_bib22","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.modpat.2025.100925_bib23","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/cjp2.112","article-title":"Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients","volume":"4","author":"Dodson","year":"2018","journal-title":"J Pathol Clin Res"},{"key":"10.1016\/j.modpat.2025.100925_bib25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/PAI.0000000000001071","article-title":"Lessons learned, challenges taken, and actions made for \u201cprecision\u201d immunohistochemistry. Analysis and perspectives from the NordiQC proficiency testing program","volume":"31","author":"Nielsen","year":"2023","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.modpat.2025.100925_bib26","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib27","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib28","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/jcp.2003.007724","article-title":"Best Practice No 176: updated recommendations for HER2 testing in the UK","volume":"57","author":"Ellis","year":"2004","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.modpat.2025.100925_bib30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib31","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO.2013.54.2530","article-title":"2013 update of the American Society of Clinical Oncology\/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers","volume":"32","author":"Lambein","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.modpat.2025.100925_bib33","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.modpat.2025.100925_bib34","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3390\/ijms20051115","article-title":"HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer","volume":"20","author":"Rinnerthaler","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.modpat.2025.100925_bib35","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41523-021-00343-4","article-title":"Evolution of HER2-low expression from primary to recurrent breast cancer","volume":"7","author":"Miglietta","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.modpat.2025.100925_bib39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10549-021-06365-7","article-title":"HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer","volume":"190","author":"de Moura Leite","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.modpat.2025.100925_bib40","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41379-022-01019-5","article-title":"HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles","volume":"35","author":"Zhang","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2025.100925_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-16898-6","article-title":"HER2-low breast cancer shows a lower immune response compared to HER2-negative cases","volume":"12","author":"van den Ende","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.modpat.2025.100925_bib42","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","article-title":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","volume":"22","author":"Denkert","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101592","article-title":"Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis","volume":"8","author":"Molinelli","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.modpat.2025.100925_bib44","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.3390\/cancers13112824","article-title":"HER2-low breast cancer: molecular characteristics and prognosis","volume":"13","author":"Agostinetto","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.modpat.2025.100925_bib45","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12282-021-01303-3","article-title":"The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status","volume":"29","author":"Horisawa","year":"2022","journal-title":"Breast Cancer"},{"key":"10.1016\/j.modpat.2025.100925_bib46","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.3390\/cancers13236059","article-title":"Prognostic value of HER2-low expression in non-metastatic triple-negative breast cancer and correlation with other biomarkers","volume":"13","author":"Jacot","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.modpat.2025.100925_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.modpat.2025.100925_bib48","article-title":"HER2-low breast cancer: incidence, clinicopathologic features, and survival outcomes from real-world data of a large nationwide cohort","volume":"36","author":"Baez-Navarro","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2025.100925_bib49","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13073-022-01104-z","article-title":"Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas","volume":"14","author":"Berrino","year":"2022","journal-title":"Genome Med"},{"key":"10.1016\/j.modpat.2025.100925_bib50","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.3390\/cancers14153774","article-title":"Targeted approaches to HER2-low breast cancer: current practice and future directions","volume":"14","author":"Lai","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.modpat.2025.100925_bib51","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1159\/000527391","article-title":"HER2-low breast cancer: where are we?","volume":"17","author":"Molinelli","year":"2022","journal-title":"Breast Care"},{"key":"10.1016\/j.modpat.2025.100925_bib52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.hoc.2022.08.013","article-title":"Biology and treatment of HER2-low breast cancer","volume":"37","author":"Nicol\u00f2","year":"2023","journal-title":"Hematol Oncol Clin"},{"key":"10.1016\/j.modpat.2025.100925_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113371","article-title":"Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression","volume":"195","author":"Atallah","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.modpat.2025.100925_bib54","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/14712598.2020.1752176","article-title":"Biologic therapy for advanced breast cancer: recent advances and future directions","volume":"20","author":"Tarantino","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.modpat.2025.100925_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00428-023-03656-w","article-title":"Standardized pathology report for HER2 testing in compliance with 2023 ASCO\/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer","volume":"484","author":"Ivanova","year":"2024","journal-title":"Virchows Archiv"},{"key":"10.1016\/j.modpat.2025.100925_bib56","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.modpat.2025.100925_bib57","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.modpat.2025.100925_bib58","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.annonc.2023.12.001","article-title":"Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)","volume":"35","author":"Saura","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib59","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.modpat.2025.100925_bib60","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.modpat.2025.100925_bib61","article-title":"FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HR-positive","year":"2025","journal-title":"HER2-low or HER2-ultralow breast cancer"},{"key":"10.1016\/j.modpat.2025.100925_bib62","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib64","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ajcp\/aqac184","article-title":"Interobserver and interantibody reproducibility of HER2 immunohistochemical scoring in an enriched HER2-low-expressing breast cancer cohort","volume":"159","author":"Karakas","year":"2023","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.modpat.2025.100925_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100032","article-title":"Multi-institutional assessment of pathologist scoring HER2 immunohistochemistry","volume":"36","author":"Robbins","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2025.100925_bib66","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.breast.2023.06.005","article-title":"Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland -on behalf of the UK national coordinating committee for breast pathology","volume":"70","author":"Zaakouk","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.modpat.2025.100925_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.7239","article-title":"Examination of low ERBB2 protein expression in breast cancer tissue","volume":"8","author":"Fernandez","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib68","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/2159-8290.CD-22-0703","article-title":"Navigating the HER2-low paradigm in breast oncology: new standards, future horizons","volume":"12","author":"Tarantino","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.modpat.2025.100925_bib69","first-page":"815","article-title":"Low interobserver agreement among subspecialised breast pathologists in evaluating HER2-low breast cancer","volume":"77","author":"Turashvili","year":"2024","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.modpat.2025.100925_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100009","article-title":"Interobserver variation in the assessment of immunohistochemistry expression levels in HER2-negative breast cancer: can we improve the identification of low levels of HER2 expression by adjusting the criteria? An international interobserver study","volume":"36","author":"Baez-Navarro","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2025.100925_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104127","article-title":"Interobserver consistency and diagnostic challenges in HER2-ultralow breast cancer: a multicenter study","volume":"10","author":"Wu","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.modpat.2025.100925_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.834651","article-title":"HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer","volume":"9","author":"Venetis","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.modpat.2025.100925_bib73","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.1005","article-title":"Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): the impact of repeat biopsies","volume":"41","author":"Bar","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib74","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2409343","article-title":"Stable or at least once HER2-low status during neoadjuvant chemotherapy confers survival benefit in patients with breast cancer","volume":"56","author":"Zhao","year":"2024","journal-title":"Ann Med"},{"issue":"5 Suppl","key":"10.1016\/j.modpat.2025.100925_bib75","article-title":"Outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR+) breast cancer patients: characterization of the molecular phenotype in combination with molecular subtyping","volume":"83","author":"Denkert","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.modpat.2025.100925_bib76","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231152842","article-title":"The HER2-low revolution in breast oncology: steps forward and emerging challenges","volume":"15","author":"Nicol\u00f2","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.modpat.2025.100925_bib77","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jcp-2022-208632","article-title":"UK recommendations for HER2 assessment in breast cancer: an update","volume":"76","author":"Rakha","year":"2023","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.modpat.2025.100925_bib78","first-page":"107","article-title":"Breast Cancer Expert Committee of China Anti-Cancer Association; Cancer Drug Clinical Research Committee of China Anti-Cancer Association. Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)","volume":"4","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"10.1016\/j.modpat.2025.100925_bib79","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/his.15275","article-title":"Best practices for achieving consensus in HER2-low expression in breast cancer: current perspectives from practising pathologists","volume":"85","author":"Tozbikian","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.modpat.2025.100925_bib80","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1309\/AJCPQRAG67GJRPMT","article-title":"The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma","volume":"137","author":"Yildiz-Aktas","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.modpat.2025.100925_bib81","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/PAS.0b013e31820e6237","article-title":"The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study","volume":"35","author":"Tong","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2025.100925_bib82","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/dc.22973","article-title":"Estrogen, progesterone, and HER-2 receptor immunostaining in cytology: the effect of varied fixation on human breast cancer cells","volume":"41","author":"Maleki","year":"2013","journal-title":"Diagn Cytopathol"},{"issue":"24","key":"10.1016\/j.modpat.2025.100925_bib83","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.3390\/cancers14246200","article-title":"HER2-low status is not accurate in breast cancer core needle biopsy samples: an analysis of 5610 consecutive patients","volume":"14","author":"Lu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.modpat.2025.100925_bib84","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/cncr.35101","article-title":"HER2-low heterogeneity between primary and paired recurrent\/metastatic breast cancer: implications in treatment and prognosis","volume":"130","author":"Lin","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.modpat.2025.100925_bib85","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/his.15346","article-title":"Discordance of human epidermal growth factor receptor 2-low status between breast primary and distant metastases with clinical-pathological correlation","volume":"86","author":"Yang","year":"2025","journal-title":"Histopathology"},{"key":"10.1016\/j.modpat.2025.100925_bib86","article-title":"Abstract, HER2-18 determination of HER2-low status in tumors of patients with unresectable and\/or metastatic breast cancer in DESTINY-Breast04","author":"Prat","year":"2022","journal-title":"San Antonio Breast Cancer Symposium"},{"key":"10.1016\/j.modpat.2025.100925_bib87","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/his.15273","article-title":"Quantitative comparison of immunohistochemical HER2-low detection in an interlaboratory study","volume":"85","author":"Hempenius","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.modpat.2025.100925_bib88","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.mpdhp.2024.12.001","article-title":"The UK National External Quality Assessment Scheme for Immunocytochemistry and In-Situ Hybridisation (UK NEQAS ICC & ISH) HER2-low EQA programme: a review of results and factors influencing successful staining","volume":"31","author":"Parry","year":"2025","journal-title":"Diagn Histopathol"},{"key":"10.1016\/j.modpat.2025.100925_bib89","doi-asserted-by":"crossref","DOI":"10.4061\/2010\/814176","article-title":"Analytical validation of a highly quantitative, sensitive, accurate, and reproducible assay (HERmark\u00ae) for the measurement of HER2 total protein and HER2 homodimers in FFPE breast cancer tumor specimens","volume":"2010","author":"Larson","year":"2010","journal-title":"Pathol Res Int"},{"key":"10.1016\/j.modpat.2025.100925_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-015-0543-x","article-title":"Quantitative measurement of HER2 expression in breast cancers: comparison with \u2018real-world\u2019routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival","volume":"17","author":"Yardley","year":"2015","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.modpat.2025.100925_bib91","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2353\/ajpath.2010.090711","article-title":"Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome","volume":"176","author":"Harigopal","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.modpat.2025.100925_bib92","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/s41374-022-00804-9","article-title":"Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer","volume":"102","author":"Moutafi","year":"2022","journal-title":"Lab Invest"},{"key":"10.1016\/j.modpat.2025.100925_bib93","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/modpathol.2016.176","article-title":"A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2","volume":"30","author":"Jensen","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2025.100925_bib94","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3390\/cancers12071902","article-title":"ERBB2 mRNA expression and response to ado-trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"12","author":"Griguolo","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.modpat.2025.100925_bib95","article-title":"Prediction of response to anti-HER2 therapy using a multigene assay","volume":"38","author":"Atallah","year":"2025","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2025.100925_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100408","article-title":"Correlation of HER2 protein level with mRNA level quantified by RNAscope in breast cancer","volume":"37","author":"Li","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2025.100925_bib97","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/his.14780","article-title":"Refining the definition of HER2-low class in invasive breast cancer","volume":"81","author":"Atallah","year":"2022","journal-title":"Histopathology"},{"key":"10.1016\/j.modpat.2025.100925_bib98","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1373\/clinchem.2008.120576","article-title":"Cell lines as candidate reference materials for quality control of ERBB2 amplification and expression assays in breast cancer","volume":"55","author":"Xiao","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.modpat.2025.100925_bib99","series-title":"Bond\u2122 Oracle\u2122 HER2 IHC System Interpretation Guide","year":"2022"},{"key":"10.1016\/j.modpat.2025.100925_bib100","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5858\/arpa.2017-0330-OA","article-title":"Quantitative assessment of immunohistochemistry laboratory performance by measuring analytic response curves and limits of detection","volume":"142","author":"Sompuram","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.modpat.2025.100925_bib101","doi-asserted-by":"crossref","first-page":"993","DOI":"10.5858\/arpa.2023-0950-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer","volume":"147","author":"Wolff","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.modpat.2025.100925_bib102","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/his.15117","article-title":"Practical approach to scoring HER2 immunohistochemistry in breast cancer in the wake of updated guidelines","volume":"84","author":"Tan","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.modpat.2025.100925_bib103","doi-asserted-by":"crossref","first-page":"677","DOI":"10.4103\/IJPM.IJPM_983_20","article-title":"HER2 testing by immunohistochemistry in breast cancer: a multicenter proficiency ring study","volume":"64","author":"Pauzi","year":"2021","journal-title":"Indian J Pathol Microbiol"},{"key":"10.1016\/j.modpat.2025.100925_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155472","article-title":"Artificial intelligence for assisted HER2 immunohistochemistry evaluation of breast cancer: a systematic review and meta-analysis","volume":"260","author":"Wu","year":"2024","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.modpat.2025.100925_bib105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13000-025-01624-3","article-title":"Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff : HER2 IHC scoring concordance in breast cancer","volume":"20","author":"Wrobel","year":"2025","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.modpat.2025.100925_bib106","author":"McKelvey"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395225002236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395225002236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:49:42Z","timestamp":1781336982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395225002236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0893395225002236"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2025.100925","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-Low and Ultralow Categories","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2025.100925","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"100925"}}